U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Moxidectin

Last Revision: August 15, 2024.

Estimated reading time: 1 minute

CASRN: 113507-06-5

image 135023246 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of moxidectin during breastfeeding. However, amounts in breastmilk appear to be low and would not be expected to cause any adverse effects in breastfed infants. Although labeling recommends withholding breastfeeding for 7 days after a dose, this appears to be unnecessary; however, withholding breastfeeding for 1 day would decrease infant exposure by 40%. Until more data become available, moxidectin should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Twelve lactating women who averaged 29.6 weeks (range 21 to 100 weeks) postpartum and had weaned their infants were given moxidectin 8 mg orally as a single dose. A breast pump was used to collect milk samples for at least 30 days, and in some, at various times for up to 90 days after the dose. The total amount of drug excreted into breastmilk averaged 0.056 mg over the study period, which was 8.7% (SD 3.2%) of the weight-adjusted maternal dose. The amount of moxidectin excreted into breastmilk tended to be higher in some women with lower maternal body weight.[1]

A physiologically based pharmacokinetic (PBPK) model using data from this study was developed and compared to results of animal exposure studies. It concluded that even with no interruption of breastfeeding after a dose, the dose that an exclusively breastfed infant would receive would be well below the no observed adverse effect level (NOAEL) in animal studies. Withholding breastfeeding for 24 hours would result in about a 40% decrease in infant exposure.[2]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother 2011;55:5200-4. [PMC free article: PMC3195050] [PubMed: 21896908]
2.
Wood ND, Smith D, Kinrade SA, et al. The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation. PLoS Negl Trop Dis 2024;18:e0012351. [PMC free article: PMC11326704] [PubMed: 39102440]

Substance Identification

Substance Name

Moxidectin

CAS Registry Number

113507-06-5

Drug Class

Breast Feeding

Lactation

Milk, Human

Anti-Infective Agents

Antiparasitic Agents

Anthelmintics

Antinematodal Agents

Insecticides

Macrolides

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK525501PMID: 30222293

Views

Related information

Similar articles in PubMed

  • Review Anidulafungin.[Drugs and Lactation Database (...]
    Review Anidulafungin.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Everolimus.[Drugs and Lactation Database (...]
    Review Everolimus.
    . Drugs and Lactation Database (LactMed®). 2006
  • Review Sumatriptan.[Drugs and Lactation Database (...]
    Review Sumatriptan.
    . Drugs and Lactation Database (LactMed®). 2006
  • Sesquiterpenoids from the Mangrove-Derived Aspergillus ustus 094102.[Mar Drugs. 2022]
    Sesquiterpenoids from the Mangrove-Derived Aspergillus ustus 094102.
    Gui P, Fan J, Zhu T, Fu P, Hong K, Zhu W. Mar Drugs. 2022 Jun 22; 20(7). Epub 2022 Jun 22.
  • Review Sirolimus.[Drugs and Lactation Database (...]
    Review Sirolimus.
    . Drugs and Lactation Database (LactMed®). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...